{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:06Z","timestamp":1789726266367,"version":"4.0.1"},"reference-count":24,"publisher":"Korean Diabetes Association","issue":"1","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["e-dmj.org"],"crossmark-restriction":true},"short-container-title":["Diabetes Metab J"],"published-print":{"date-parts":[[2023,1,31]]},"abstract":"Background: No meta-analysis has analysed efficacy and safety of fast-acting aspart insulin (FIAsp) with insulin pump in type 1 diabetes mellitus (T1DM).Methods: Electronic databases were searched for randomised controlled trials (RCTs) involving T1DM patients on insulin pump receiving FIAsp in intervention arm, and placebo\/active comparator insulin in control arm. Primary outcome was to evaluate changes in 1- and 2-hour post-prandial glucose (1hPPG and 2hPPG). Secondary outcomes were to evaluate alterations in percentage time with blood glucose <3.9 mmol\/L (hypoglycaemia), time in range (TIR) blood glucose 3.9 to 10 mmol\/L, insulin requirements and adverse events.Results: Data from four RCTs involving 640 patients was analysed. FIAsp use in insulin pump was associated with significantly greater lowering of 1hPPG (mean difference [MD], \u20131.35 mmol\/L; 95% confidence interval [CI], \u20131.72 to \u20130.98; <i>P<\/i><0.01; I<sup>2<\/sup>=63%) and 2hPPG (MD, \u20131.19 mmol\/L; 95% CI, \u20131.38 to \u20131.00; <i>P<\/i><0.01; I<sup>2<\/sup>=0%) as compared to controls. TIR was comparable among groups (MD, 1.06%; 95% CI, \u20133.84 to 5.96; <i>P<\/i>=0.67; I<sup>2<\/sup>=70%). Duration of blood glucose <3.9 mmol\/L was lower in FIAsp group, approaching significance (MD, \u20130.91%; 95% CI, \u20131.84 to 0.03; <i>P<\/i>=0.06; I<sup>2<\/sup>=0%). Total hypoglycaemic episodes (risk ratio [RR], 1.35; 95% CI, 0.55 to 3.31; <i>P<\/i>=0.51; I<sup>2<\/sup>=0%), severe hypoglycaemia (RR, 2.26; 95% CI, 0.77 to 6.66; <i>P<\/i>=0.14), infusion site reactions (RR, 1.35; 95% CI, 0.63 to 2.93; <i>P<\/i>=0.77; I<sup>2<\/sup>=0%), and treatment-emergent adverse events (RR, 1.13; 95% CI, 0.80 to 1.60; <i>P<\/i>=0.50; I<sup>2<\/sup>=0%) were comparable.Conclusion: FIAsp use in insulin pump is associated with better post-prandial glycaemic control with no increased hypoglycaemia or glycaemic variability.<\/jats:p>","DOI":"10.4093\/dmj.2022.0035","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T05:55:16Z","timestamp":1656050116000},"page":"72-81","update-policy":"https:\/\/doi.org\/10.4093\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis"],"prefix":"10.4093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4915-8805","authenticated-orcid":true,"given":"Deep","family":"Dutta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritin","family":"Mohindra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2567","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2016.0421"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0514-8"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12468"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00834-5"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0500"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.08.039"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.ad"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3310\/hta4100"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14355"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13610"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2020.0083"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01087-x"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2021.106087"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14447"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14461"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2010.12.003"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00685-0"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13798"},{"key":"ref21","volume-title":""},{"key":"ref22","volume-title":""},{"key":"ref23","volume-title":""},{"key":"ref24","volume-title":"How much does insulin cost? Here\u2019s how 28 brands and generics compare","author":"Lee"}],"container-title":["Diabetes & Metabolism Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.e-dmj.org\/upload\/pdf\/dmj-2022-0035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2022.0035","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.e-dmj.org\/upload\/pdf\/dmj-2022-0035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T07:00:35Z","timestamp":1675321235000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2022.0035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"URL":"https:\/\/doi.org\/10.4093\/dmj.2022.0035","relation":{},"ISSN":["2233-6079","2233-6087"],"issn-type":[{"value":"2233-6079","type":"print"},{"value":"2233-6087","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]},"assertion":[{"value":"2022-02-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-24","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-31","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}